[1]刘 璇,陈珍珍.达格列净联合二甲双胍在2型糖尿病治疗中的临床疗效[J].医学信息,2025,38(02):116-119.[doi:10.3969/j.issn.1006-1959.2025.02.021]
　LIU Xuan,CHEN Zhenzhen.Clinical Efficacy of Dapagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2025,38(02):116-119.[doi:10.3969/j.issn.1006-1959.2025.02.021]
点击复制

达格列净联合二甲双胍在2型糖尿病治疗中的临床疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年02期
页码:
116-119
栏目:
论著
出版日期:
2025-01-15

文章信息/Info

Title:
Clinical Efficacy of Dapagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus
文章编号:
1006-1959（2025）02-0116-04
作者:
刘 璇1; 陈珍珍2
西安市人民医院/西安市第四医院内分泌科1，老年病科2，陕西 西安 710004
Author(s):
LIU Xuan1;  CHEN Zhenzhen2
Department of Endocrinology1, Department of Geriatrics2, Xi′an People′s Hospital/Xi′an Fourth Hospital, Xi′an 710004, Shaanxi, China
关键词:
2型糖尿病; 达格列净; 盐酸二甲双胍; 血糖水平; 血脂水平; 胰岛功能
Keywords:
Type 2 diabetes mellitus;  Dapagliflozin;  Metformin hydrochloride;  Blood glucose level;  Blood lipid level;  Islet function
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2025.02.021
文献标志码:
A
摘要:
目的 探讨达格列净联合盐酸二甲双胍在2型糖尿病患者中的临床疗效。方法 收集2021年5月-2022年5月在西安市人民医院内分泌科就诊的160例2型糖尿病患者作为研究对象，按照随机数字表法将其分为对照组（80例）和治疗组（80例）。对照组给予盐酸二甲双胍治疗，治疗组采用达格列净联合二甲双胍治疗，比较两组糖脂代谢水平、胰岛功能指标及不良反应发生率。结果 两组治疗后血糖水平均下降，且治疗组优于对照组，差异有统计学意义（P＜0.05）；两组治疗后血脂水平（TG、TC、LDL-C）均下降，且治疗组优于对照组，差异有统计学意义（P＜0.05）；两组治疗后空腹胰岛素（FINS）、餐后2 h胰岛素（2 h INS）、胰岛β细胞功能指数（HOMA-β）均升高，胰岛素抵抗指数（HOMA-IR）均降低，且治疗组优于对照组，差异有统计学意义（P＜0.05）；治疗组不良反应发生率（11.25%）与对照组（17.50%）比较，差异无统计学意义（P＞0.05）。结论 达格列净联合二甲双胍治疗2型糖尿病患者，能有效改善血糖、胰岛功能，且不良反应的发生率低。
Abstract:
Objective To investigate the clinical efficacy of dapagliflozin combined with metformin hydrochloride in patients with type 2 diabetes mellitus. Methods A total of 160 patients with type 2 diabetes mellitus who were treated in the Department of Endocrinology of Xi′an People’s Hospital from May 2021 to May 2022 were collected as subjects. They were divided into control group (80 patients) and treatment group (80 patients) according to the random number table method. The control group was treated with metformin hydrochloride, and the treatment group was treated with dapagliflozin combined with metformin. The levels of glucose and lipid metabolism, islet function indexes and the incidence of adverse reactions were compared between the two groups. Results The blood glucose levels of the two groups decreased after treatment, and those of the treatment group were better than those of the control group, the difference were statistically significant (P<0.05). The blood lipid levels (TG, TC, LDL-C) of the two groups decreased after treatment, and those of the treatment group were better than those of the control group, the difference were statistically significant (P<0.05). After treatment, fasting insulin (FINS), 2 h postprandial insulin (2 h INS), islet β cell function index (HOMA-β) in the two groups increased, and insulin resistance index (HOMA-IR) decreased, and those in the treatment group were better than the control group, the differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the treatment group (11.25%) and the control group (17.50%) (P>0.05). Conclusion Dapagliflozin combined with metformin can effectively improve the blood glucose and islet function of patients with type 2 diabetes mellitus, and the incidence of adverse reactions is low.

参考文献/References:

[1]Unnikrishnan R,Anjana RM,Mohan V.Diabetes mellitus and its complications in India[J].Nat Rev Endocrinol,2016,12(6):357-370.[2]Xiang G,Huang X,Wang T,et al.The impact of sitagliptin on macrophage polarity and angiogenesis in the osteointegration of titanium implants in type 2 diabetes[J].Biomed Pharmacother,2020,126:110078.[3]Packer M,Anker SD,Butler J,et al.Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure[J].N Engl J Med,2020,383(15):1413-1424.[4]Varzideh F,Kansakar U,Santulli G.SGLT2 inhibitors in cardiovascular medicine[J].Eur Heart J Cardiovasc Pharmacother,2021,7(4):e67-e68.[5]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.[6]Ali MK,Pearson-Stuttard J,Selvin E,et al.Interpreting global trends in type 2 diabetes complications and mortality[J].Diabetologia,2022,65(1):3-13.[7]Knowler WC,Barrett-Connor E,Fowler SE,et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin[J].N Engl J Med,2002,346(6):393-403.[8]Diabetes Prevention Program Research Group,Crandall J,Schade D,et al.The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes[J].J Gerontol A Biol Sci Med Sci,2006,61(10):1075-1081.[9]Chiasson JL,Josse RG,Gomis R,et al.Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial[J].Lancet,2002,359(9323):2072-2077.[10]Forslund K,Hildebrand F,Nielsen T,et al.Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota[J].Nature,2015,528(7581):262-266.[11]Morita Y,Nogami M,Sakaguchi K,et al.Enhanced Release of Glucose Into the Intraluminal Space of the Intestine Associated With Metformin Treatment as Revealed by Fluorodeoxyglucose PET-MRI[J].Diabetes Care,2020,43(8):1796-1802.[12]刘金瑞,张靖华,吴秋杰,等.钠-葡萄糖协同转运蛋白2抑制剂达格列净对2型糖尿病肾病肾移植患者血糖及肾功能的影响[J].临床内科杂志,2022,39(2):97-100.[13]翟屹,房红芸,于文涛,等.2010-2012年中国成年人腰围水平与中心型肥胖流行特征[J].中华预防医学杂志,2017,51(6):506-512.[14]Jayawardene D,Ward GM,O’Neal DN,et al.New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?[J].Heart Lung Circ,2014,23(11):997-1008.[15]李晶,蔺丽媛,潘娟,等.钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病合并冠心病患者血清趋化素、血脂水平及胰岛素用量的影响[J].中国医师杂志,2022,24(4):527-530,537.[16]Scheen AJ,Paquot N.Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence[J].Diabetes Metab,2014,40(6 Suppl 1):S4-S11.[17]付强,刘丽秋,杨沿浪,等.达格列净对早期2型糖尿病肾病足细胞损伤及氧化应激的影响[J].实用药物与临床,2021,24(2):146-149.[18]李金生,张一平,任苗苗.达格列净联合二甲双胍治疗2型糖尿病肾病的临床疗效研究[J].黑龙江医学,2020,44(7):948-950.[19]马文莉.雷公藤多苷片联合ACE抑制剂、SGLT2抑制剂对糖尿病肾病Ⅳ期患者肾功能和蛋白尿水平的影响[J].中国实用医刊,2022,49(16):120-123.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(02):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(02):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(02):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(02):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
　LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Journal of Medical Information,2018,31(02):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[7]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
　DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Journal of Medical Information,2018,31(02):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[8]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
　LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(02):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[9]刘小红.长效胰岛素联合口服降糖药治疗2型糖尿病的 疗效与安全性评价[J].医学信息,2018,31(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
　LIU Xiao-hong.Efficacy and Safety of Long Acting Insulin Combined with Oral Hypoglycemic Agents in Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(02):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
[10]鲍 哲,杨升伟,柯赛赛,等.益生元对2型糖尿病患者糖脂代谢的影响[J].医学信息,2018,31(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
　BAO Zhe,YANG Sheng-wei,KE Sai-sai,et al.Effect of Prebiotics on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes mellitus[J].Journal of Medical Information,2018,31(02):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
[11]孙寿广.达格列净治疗2型糖尿病的研究进展[J].医学信息,2018,31(19):37.[doi:10.3969/j.issn.1006-1959.2018.19.013]
　SUN Shou-guang.Progress in the Study of Dapagliflozin in the Treatment of Type 2 Diabetes[J].Journal of Medical Information,2018,31(02):37.[doi:10.3969/j.issn.1006-1959.2018.19.013]
[12]董 健.达格列净治疗2型糖尿病的疗效及其对体质指数的影响[J].医学信息,2020,33(07):158.[doi:10.3969/j.issn.1006-1959.2020.07.052]
　DONG Jian.The Therapeutic Effect of Dapagliflozin on Type 2 Diabetes and Its Influence on Body Mass Index[J].Journal of Medical Information,2020,33(02):158.[doi:10.3969/j.issn.1006-1959.2020.07.052]
[13]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(02):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[14]廖 萌,淦作梅.达格列净联合二甲双胍对2型糖尿病患者尿蛋白水平及心血管不良事件的影响[J].医学信息,2024,37(13):122.[doi:10.3969/j.issn.1006-1959.2024.13.025]
　Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type Diabetes Mellitus.Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2024,37(02):122.[doi:10.3969/j.issn.1006-1959.2024.13.025]

更新日期/Last Update: 1900-01-01